Zarębska-Michaluk Dorota, Hu Chenlin, Brzdęk Michał, Flisiak Robert, Rzymski Piotr
Department of Infectious Diseases, Jan Kochanowski University, 25-369 Kielce, Poland.
College of Pharmacy, University of Houston, Houston, TX 77204, USA.
Vaccines (Basel). 2022 Jul 30;10(8):1223. doi: 10.3390/vaccines10081223.
In the light of the lack of authorized COVID-19 vaccines adapted to the Omicron variant lineage, the administration of the first and second booster dose is recommended. It remains important to monitor the efficacy of such an approach in order to inform future preventive strategies. The present paper summarizes the research progress on the effectiveness of the first and second booster doses of COVID-19. It also discusses the potential approach in vaccination strategies that could be undertaken to maintain high levels of protection during the waves of SARS-CoV-2 infections. Although this approach can be based, with some shortcomings, on the first-generation vaccines, other vaccination strategies should be explored, including developing multiple antigen-based (multivariant-adapted) booster doses with enhanced durability of immune protection, e.g., through optimization of the half-life of generated antibodies.
鉴于缺乏经授权的适应奥密克戎变异株谱系的新冠疫苗，建议接种第一剂和第二剂加强针。监测这种方法的效果对于为未来的预防策略提供依据仍然很重要。本文总结了新冠疫苗第一剂和第二剂加强针有效性的研究进展。它还讨论了在新冠病毒感染浪潮期间为维持高水平保护而可采取的疫苗接种策略中的潜在方法。尽管这种方法在一定程度上可以基于第一代疫苗，但仍应探索其他疫苗接种策略，包括开发具有增强免疫保护持久性的多抗原（多变异株适应）加强针，例如通过优化产生抗体的半衰期。
